Is Quizartinib already on the market in China? What is its time to market and related policies?
Quizartinib has not yet been approved for marketing in China, so patients cannot purchase the drug through regular domestic channels. Quizartinib is mainly used to treat FLT3 mutation-positive acute myeloid leukemia (AML) and has been approved in many countries and regions. However, in China, relevant regulatory authorities have not yet approved its marketing, meaning that the drug has not yet been included in domestic treatment protocols.
Since Quizartinib is not on the market in China, patients can only purchase the drug through overseas channels. In overseas markets, patients can choose to purchase the original version or the cheaper generic version. The price of original Quizartinib is usually higher, while the price of generic drugs is relatively more affordable. For example, the generic version of Quizartinib produced by Lucius, Laos, has specifications including 17.7 mg 14 tablets and 26.5 mg 14 tablets, priced at more than 1,000 yuan. This makes generic drugs the first choice for many patients, especially those looking to reduce their financial burden.

For patients, when purchasing generic drugs, they need to pay special attention to choosing reliable channels to ensure the legality and quality of the drugs. Although the price of generic drugs is lower, their active ingredients are basically the same as the original drugs and can theoretically exert the same therapeutic effect. Patients should be cautious when purchasing and ensure that they are purchased through certified drug suppliers or reputable channels to avoid purchasing counterfeit drugs or products of substandard quality.
In general, quizartinib is not yet available in China, so patients can only purchase it through overseas channels, and when choosing to purchase original drugs or generic drugs, they need to weigh the differences in price and efficacy based on personal circumstances. When purchasing, you also need to ensure the formality of the source of the medicine to ensure that the medicine used is safe and effective.
Reference materials:https://go.drugbank.com/drugs/DB12874
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)